Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire) - Aug 11, 2023 - P1/2a | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "Plus Therapeutics, Inc...reported positive data from the ReSPECT-LM clinical study evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases (LM) at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California....Safety: No dose limiting toxicities were observed and a maximum tolerated dose or maximum feasible dose was not reached. Most adverse events were mild (Grade 1, 58.7%) or moderate (Grade 2, 24%), with the majority not related to treatment. Survival: Currently, 5 of the 10 treated patients remain alive with a median overall survival (OS) of 10 months."
New P1/2 trial • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|